FDA allows a Phase II trial of Athersys' MultiStem

11/10/2010 | MassDevice.com (Boston)

The FDA has granted approval to Athersys to conduct a midstage trial of MultiStem, an experimental stem cell therapy derived from bone marrow, in patients with inflammatory bowel disease. Athersys CEO Gil Van Bokkelen said Pfizer will shoulder the cost of the 126-patient study as part of a development and marketing deal signed in December.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD